Ambu consensus stays supportive, analysts see upside for the shares
23.06.2026 - 21:01:24 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:58.
Ambu (DK0060946788) sits on a cautious but supportive analyst base today. The medical device group is listed in Copenhagen, where the shares trade notably below the average 12-month price target cited by several research houses.Consensus data from Investing.com
What analysts are pricing in
According to a recent consensus overview, eight analysts currently cover Ambu, with four rating the stock Buy and four advising Hold, while none place a Sell recommendation on the company.Consensus data from Investing.com The average 12-month price target is reported at 88.8 Danish kroner, with a high estimate of 116.4 kroner and a low estimate of 65 kroner, implying a meaningful spread of expectations across the coverage universe.Consensus data from Investing.com
Based on these projections, Ambu is cited as having a potential upside of roughly 41.6 percent from the current share price, calculated against the average target of 88.8 kroner.Consensus data from Investing.com The consensus rating is described as Buy, reflecting the tilt of the recommendations despite the sizeable proportion of Hold ratings in the mix.Consensus data from Investing.com
Where the Ambu stock trades now
Ambu’s primary listing is on Nasdaq Copenhagen under the ticker AMBU B, where the shares represent exposure to single-use medical devices used in hospitals and emergency services.Company profile on MarketBeat In the U.S. over-the-counter market, the Ambu A/S ADR with the symbol AMBBY most recently changed hands at 9.51 dollars, with the last recorded trade on June 22, 2026 and a daily move of minus 1.96 percent on the session.Price and volume data from MarketBeat
On that U.S. venue, MarketBeat cites a market capitalization of about 2.23 billion dollars for Ambu and a trailing price-to-earnings ratio of 33.96, based on trailing twelve-month earnings per share of 0.28 dollars.Valuation metrics from MarketBeat The ADR listing is complemented by an indicated dividend yield of 0.32 percent, which plays only a minor role in the overall return profile of the shares.Dividend data from MarketBeat
All news and key data on the Ambu shares
For investors following Ambu, the topic page aggregates current news, price data and regulatory disclosures alongside the company’s own investor updates.
The product behind the stock
Ambu generates its revenue with single-use endoscopy and diagnostic devices, which are designed to reduce infection risk and improve hospital workflow.Ambu investor information A representative product line is the Ambu aScope series of single-use endoscopes, used in bronchoscopy and airway procedures, which competes with reusable scopes from larger peers in the global medtech sector.Product details on Ambu aScope
Where the Ambu shares trade today
The Ambu shares (DK0060946788) trade on 2026-06-23, 20:16 on Nasdaq Copenhagen at an indicative level of around 62 Danish kroner, based on recent Copenhagen pricing aligned with the ADR valuation in U.S. trading.
Ambu at a glance
- Company: Ambu A/S
- ISIN: DK0060946788
- WKN: A1J3LA
- Ticker: AMBU B
- Trading venue: Nasdaq Copenhagen
- Price (as of 2026-06-23, 20:16): 62 DKK
- Market cap: 2.23 billion USD (as of 2026-06-22)
- Sector / industry: Health Care / Medical Devices
- Index membership: Mid-cap segment of the Copenhagen market
- Next earnings date: 2026-08-06
This article is for informational purposes only and does not constitute investment advice, a securities recommendation or an offer to buy or sell any financial instrument. Ambu and all other companies mentioned are subject to market risks and corporate developments that may change without notice. Retail investors should conduct their own research or consult a qualified financial advisor before making investment decisions.
